Tessa Romero
Stock Analyst at JP Morgan
(2.44)
# 974
Out of 5,218 analysts
61
Total ratings
45.24%
Success rate
44.14%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Upstream Bio | Initiates Coverage On: Overweight | 38 | 20.33 | 86.92% | 1 | Nov 5, 2024 | |
Neumora Therapeutics | Downgrades: Neutral | 18 15 | 10.29 | 45.77% | 4 | Nov 5, 2024 | |
Dyne Therapeutics | Downgrades: Neutral | 43 35 | 25.75 | 35.92% | 4 | Oct 24, 2024 | |
Seres Therapeutics | Downgrades: Underweight | n/a | n/a | n/a | 2 | Oct 24, 2024 | |
Scholar Rock Holding | Maintains: Overweight | 18 31 | 42.06 | -26.3% | 5 | Oct 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 55 68 | 38.47 | 76.76% | 5 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 65 71 | 48.66 | 45.91% | 4 | Sep 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 32 29 | 7.47 | 288.22% | 3 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 30 31 | 27.61 | 12.28% | 8 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reinstates: Neutral | 46 | 39.09 | 17.68% | 6 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 29 25 | 17.3 | 44.51% | 6 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 20 | 6.92 | 189.02% | 1 | Nov 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Underweight | 8 7 | 9.37 | -25.29% | 5 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 54 55 | 40.07 | 37.26% | 2 | Apr 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 39 36 | n/a | n/a | 4 | Jun 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Overweight | 140 150 | n/a | n/a | 1 | Mar 2, 2021 |